MEMPHASYS LIMITED. — Board/Management Information 2014

Feb 10, 2014

==> picture [55 x 49] intentionally omitted <==

==> picture [55 x 49] intentionally omitted <==

==> picture [55 x 49] intentionally omitted <==

==> picture [24 x 96] intentionally omitted <==

==> picture [12 x 96] intentionally omitted <==

==> picture [55 x 48] intentionally omitted <==

==> picture [55 x 48] intentionally omitted <==

==> picture [55 x 48] intentionally omitted <==

Co Secret mpany ary Change

Sydney, Australia 10[th] Fe b ruary 2014 – NuSe p Holdings Ltd (ASX : NSP). Th e Board of NuSep is please d to announce the a p pointed o f Ms Eliss a Hansen o f Boardro o m Pty Limite d as Company Secretary. Ms H ansen re p laces Dr. S tephen v a n der My e who fille d the po s ition in an interim m e asure w h ile the Co m pany reviewed its c orporate a nd company secret a rial requir e ments.

The B o ard would like to th a nk Dr van der Mye f o r his sup p ort and a s sistance d uring this time. D r van der M ye remains a non- e xecutive D irector of NuSep.

Ms H a nsen is a n experienced Chartered Se c retary wi t h over 1 5 years’ e xperienc e , advising manag e ment and boards o n investo r relations , governa n ce, com p liance an d other corporate i s sues.

-END-

About NuSep

NuSep (ASX: NSP) is a publicly listed l i fe science s company that sells p roducts int o the glob a l BioSep a rations mar k et. The co m pany has o f fices in bot h Sydney Au s tralia and A t lanta, USA.

With a 3 0 year he r itage in biological sep a rations, Nu S ep has forged a worl d class rep u tation for it s innovati v e yet sim p le biological separatio n technique s based on its PrIME[1] technology . The PrIM E technol o gy has pro d uced a number of world firsts including the worl d ’s first IVF s perm sepa r ation devic e . In short NuSep has r edefined th e BioSepara t ions market through inn o vation and s implificatio n .

NuSep’ s world reno w ned resear c h team has developed a n extensive portfolio of p atented pr o ducts. In al l , NuSep c urrently manufactures, d istributes a nd sells 55 products to customers i n the USA, Europe, Asi a and Aus t ralia.

NuSep P roducts:

==> picture [12 x 17] intentionally omitted <==

• Gels – NuSep manufac t ures and s e lls precast g els includin g the innov a tive nUVie w Gels, whic h c an be visu a lised 2 min u tes after us e .

==> picture [12 x 17] intentionally omitted <==

• Separation Instruments – NuSep h as developed two unique biologic a l separation instrument s . T he Proteo m eSep can separate b i ological sa m ples into 8 fractions f o r use in t h e proteomi c market. Th e SpermSep separates s p erm for fertility treatme n ts such as I V F.

==> picture [12 x 17] intentionally omitted <==

• Biological Products – N uSep supp l ies researc h grade biological produ ct s manufact u red using it s u nique separation techn o logies. Th e se products include hu m an IgG and Albumin .

For mor e informatio n about NuS e p please vi s it the comp a ny’s websit e www.NuS e p.com

1 PrIME s tands for Pr eparative I sola t ion by M embrane E lectrophoresis NuSep Holdings Ltd Postal Address Contact Details Email info@nusep.co m 30 Richmond R d P.O. B o x 2202 Telephone +6 1 2 8415 7300 Web www.nusep.com Homebush N S W 2140 Homeb u sh West NSW 2 140 Facsimile +6 1 2 8415 7399 ABN 33 120 047 556

– 2 –

About PrIME Biologics Pte Ltd

PrIME Biologics is a Singapore based biotech company that has developed a disposable therapeutic plasma manufacturing process based on NuSep’s PrIME Technology. PrIME Biologics process is based on the Pr eparative I solation by M embrane E lectrophoresis (PrIME) technology developed by NuSep. PrIME provides disposable modular processing that is ‘electronically’ driven membrane fractionation.

The PrIME process increases product yields to over 90% relative to the existing process 50% while increasing product safety. The PrIME has been shown to remove virus, bacteria, endotoxins and prions which cause ‘Mad Cow Disease’. Further, PrIME Biologics process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers.

The initial application for the PrIME process will be the Currently Unprocessable Plasma which represents approximately 50% of all the plasma collected in many Asian countries.